查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1498418

全球過敏性結膜炎市場：依疾病類型、藥物類別、通路、國家及公司分析（2024-2032）

Global Allergic Conjunctivitis Market Report by Disease Type (Seasonal ALLERGIC Conjunctivitis, Perennial Allergic Conjunctivitis ), Drug class, Distribution Channel, Countries and Company Analysis, 2024-2032
出版日期: | 出版商: Renub Research | 英文 200 Pages | 商品交期: 最快1-2個工作天內

價格
簡介目錄

全球過敏性結膜炎市場規模預計將從2023年的19.6億美元增加到2032年的24億美元，2024年至2032年複合年增長率為2.27%。

過敏性結膜炎也可互換稱為眼睛過敏 (OA)。過敏性結膜炎是一種常見的免疫超敏反應，影響許多人。近年來，過敏性結膜炎的發生率呈上升趨勢，搔癢、紅腫等症狀在全球普遍存在，極大地影響了人們的生活品質。此外，過敏性結膜炎是一種經常未被充分診斷和治療的健康問題。這是因為很少有患者因過敏性結膜炎症狀而就醫，大多數患者接受非處方藥治療，而不輔以藥物治療。

結膜炎通常可以自我診斷，幾乎不需要進行診斷測試。因此，過敏性結膜炎的流動預計將有助於預測期內的市場成長。根據NIH 2021 年2 月發表的另一篇論文，病毒和細菌性結膜炎是感染性結膜炎的兩種常見形式，病毒感染佔急性結膜炎病例的80%，而細菌感染佔病例的50-75 %。據同一消息來源稱，在中國等國家，結膜炎的盛行率也很高。此外，根據BMC 2022年3月發表的論文，中國大陸出血性結膜炎的年平均發生率為3.58/10萬人。出血性結膜炎盛行率的增加預計將推動結膜炎治療的需求並促進市場成長。

全球過敏性結膜炎患者數量的增加和醫療服務需求的增加預計將成為市場成長的主要動力。此外，隨著患者數量的不斷增加，許多主要市場公司都專注於過敏性結膜炎治療藥物的研發活動，這也促進了過敏性結膜炎市場的成長。

根據 2022 年 4 月《Nature》雜誌發表的一篇論文，大約 10% 的樣本人群患有過敏性結膜炎。在印度，5-15歲族群過敏性結膜炎的盛行率為12.22%。此外，2021 年 1 月發表的 NCBI 論文指出，超過一半的患者報告他們的日常症狀是季節性或常年性的，大約 75% 的人認為他們的症狀很嚴重。此外，在歐洲，每10,000人中有1.2至10.6人患有春季角結膜炎。過敏性結膜炎的流動預計將推動對有效治療的需求，並有助於研究領域的成長。

此外，增加接觸污染物和化學物質也是過敏性結膜炎的原因，預計將推動過敏性結膜炎市場的預測。然而，過敏性結膜炎治療藥物的副作用可能會阻礙市場成長。相反，人們對這種疾病的認識不斷提高，為大公司投資過敏性結膜炎市場創造了機會。

北美過敏性結膜炎市場

由於有效治療方法的可用性和消費者對結膜炎的高度認識等因素，預計北美將主導市場。根據 2020 年 2 月發表的一篇National Library Medicine論文，結膜炎每年影響美國超過 600 萬人。據估計，這種疾病每年造成的損失約為 3.77 億美元至 8.57 億美元。結膜炎是該國最常見的疾病，影響15%至40%的人口，並且在春季和夏季更為常見。

此外，2021 年 1 月發表的 NCBI 論文指出，季節性或常年性過敏性結膜炎是最常見的過敏性結膜炎類型，占美國眼部過敏的 95% 以上。它影響男性和女性，影響 15% 至 40% 的人口。美國的這種結膜炎流行預計將推動對有效治療的需求，並在預測期內促進市場成長。

由於其廣泛的醫療服務和大量的結膜炎患者，預計該市場很快就會在美國佔據最大佔有率。此外，預計加拿大結膜炎的高盛行率將有助於預測期內的市場成長。BMC 2022 年 10 月發表的一篇論文估計，21% 的加拿大人患有乾眼症。結膜炎的流動預計將促進加拿大市場的成長。

該報告研究了全球過敏性結膜炎市場，並提供了市場動態、區域和細分市場分析以及主要參與者的收入分析。

目錄

第1章 簡介

第2章 研究方法

第3章 執行摘要

第4章 市場動態

  • 增長動力
  • 任務

第5章 全球過敏性結膜炎市場

第6章 全球過敏性結膜炎市佔率分析

  • 依疾病類型
  • 依藥物類別
  • 依分銷渠道
  • 依國家

第7章 疾病類型

  • 季節性過敏性結膜炎（SAC）
  • 常年性過敏性結膜炎（PAC）

第8章 藥物類別

  • 抗組織胺/肥大細胞穩定藥
  • 皮質類固醇
  • 其他

第9章 分銷通路

  • 醫院藥房
  • 網上藥店
  • 零售藥局/藥局
  • 其他

第10章 國家

  • 北美
    • 美國
    • 加拿大
  • 歐洲
    • 法國
    • 德國
    • 義大利
    • 西班牙
    • 英國
    • 比利時
    • 荷蘭
    • 土耳其
  • 亞太地區
    • 中國
    • 日本
    • 印度
    • 澳大利亞
    • 韓國
    • 泰國
    • 馬來西亞
    • 印度尼西亞
    • 紐西蘭
  • 拉丁美洲
    • 巴西
    • 墨西哥
    • 阿根廷
  • 中東/非洲
    • 南非
    • 沙烏地阿拉伯
    • 阿拉伯聯合酋長國

第11章波特五力分析

第12章 SWOT分析

第十三章主要公司分析

  • Ajanta Pharma Limited
  • Alembic Pharmaceutical Ltd.
  • Cipla Inc.
  • Indoco Remedies Ltd.
  • Johnson & Johnson
  • Novartis AG
  • Ocular Therapeutix, Inc.
  • Sun Pharmaceutical Industries Ltd.
  • Teva Pharmaceutical Industries Ltd.
簡介目錄

Allergic Conjunctivitis Market is expected to reach US$ 2.40 Billion by 2032 from US$ 1.96 Billion in 2023, with a CAGR of 2.27% during 2024-2032.

Allergic conjunctivitis interchangeably is also known as Ocular allergy (OA). It is a common immunological hypersensitivity disorder affecting numerous populations. In recent years, allergic conjunctivitis has been increasing in frequency, with symptoms of itching, redness, and swelling globally that significantly impact an individual's quality of life. Besides, allergic conjunctivitis is an often under diagnosed and undertreated health problem because very few patients with allergic conjunctivitis symptoms seek medical attention, whereas most patients manage with over-the-counter medications and complementary no pharmacological remedies.

Generally, conjunctivitis is self-diagnosable, and there is the least need to undergo any diagnostic test for this disease. Thus, the incidence of allergic conjunctivitis is expected to contribute to the market's growth during the forecast period. As per another NIH article published in February 2021, viral and bacterial conjunctivitis are the two common forms of infectious conjunctivitis, with viral infection responsible for up to 80% of all acute conjunctivitis cases and bacterial infection accounting for between 50-75% of cases of infectious conjunctivitis in children. According to the same source, countries like China also have a high incidence of conjunctivitis. Moreover, as per the BMC article published in March 2022, the average annual hemorrhagic conjunctivitis incidence was 3.58/100,000 in mainland China. The rising incidence of hemorrhagic conjunctivitis is expected to drive the demand for conjunctivitis treatment, thereby contributing to market growth.

Increase in patient population of allergic conjunctivitis worldwide and escalating demand for healthcare services is expected to majorly drive the market growth. In addition, many key market players are focusing on R&D activities to develop drugs for allergic conjunctivitis as patient population is increasing, which also drives the allergic conjunctivitis market growth.

As per the Nature article published in April 2022, approximately 10% of the sample population had allergic conjunctivitis. In India, the prevalence of allergic conjunctivitis was 12.22% among those aged between five and 15 years. Also, the NCBI article published in January 2021 mentioned that more than half of the patients report daily symptoms as seasonal or perennial and around 75% consider their symptoms to be severe. The same source also mentioned that there were between 1.2 and 10.6 cases of vernal keratoconjunctivitis per 10,000 individuals in Europe. Such incidence of allergic conjunctivitis is expected to drive the demand for effective treatment, contributing to the growth of the studied segment.

Furthermore, rise in exposure to pollutants and chemicals causes allergic conjunctivitis and is also expected to propel the allergic conjunctivitis market forecast. However, adverse reaction of allergic conjunctivitis medications can impede the growth of the market. Conversely, increase in awareness about the disease creates allergic conjunctivitis market opportunity for the key players to invest.

North America allergic conjunctivitis market

North America is expected to dominate the market, owing to factors such as the easy availability of effective treatment products and high awareness among consumers regarding conjunctivitis in the region. As per the National Library Medicine article published in February 2020, conjunctivitis affects more than 6 million people across the United States every year. The estimated cost for the disease is around USD 377 million to USD 857 million per year. Conjunctivitis is found to be the most frequent disease in the country and affects 15% to 40% of the population, and is seen frequently in spring and summer.

Also, the NCBI article published in January 2021 mentioned that seasonal or perennial allergic conjunctivitis is the most prevalent form of allergic conjunctivitis, with more than 95% of ocular allergy cases in the United States. It is observed in both sexes and affects between 15% and 40% of the population. Such prevalence of conjunctivitis in the United States is expected to drive the demand for effective treatment, thereby contributing to the market's growth during the forecast period.

Due to better healthcare services and the high number of people suffering from conjunctivitis in the United States, the market is expected to hold the largest share shortly. Also, the high prevalence of conjunctivitis in Canada is expected to contribute to the market's growth over the forecast period. As per the BMC article published in October 2022, it is estimated that 21% of Canadians have dry eyes. Such prevalence of conjunctivitis is expected to contribute to market growth in Canada.

Allergic Conjunctivitis Industry Analysis

The Allergic conjunctivitis competitive landscape includes an analysis of global and local companies which hold market shares and are well known, including Ajanta Pharma Limited, Akorn Operating Company LLC, Alembic Pharmaceutical Ltd., Cipla Inc., Indoco Remedies Ltd., Johnson & Johnson, Novartis AG, Ocular Therapeutix, Inc., Sun Pharmaceutical Industries Ltd., and Teva Pharmaceutical Industries Ltd.

Disease Types - Global Allergic Conjunctivitis Market is divided into 2 viewpoints

1. Seasonal ALLERGIC Conjunctivitis (SAC)

2. Perennial Allergic Conjunctivitis (PAC)

Drugs Class - Global Allergic Conjunctivitis Market is divided into 3 viewpoints

1. Antihistamines & Mast Cell Stabilizers

2. Corticosteroids

3. Others

Distribution Channels - Global Allergic Conjunctivitis Market is divided into 4 viewpoints

1. Hospital Pharmacies

2. Online Pharmacies

3. Retail Pharmacies & Drug Stores

4. Others

Countries - Market is divided into 25 country Allergic Conjunctivitis Industry

North America

1. United States

2. Canada

Europe

1. France

2. Germany

3. Italy

4. Spain

5. United Kingdom

6. Belgium

7. Netherlands

8. Turkey

Asia Pacific

1. China

2. Japan

3. India

4. Australia

5. South Korea

6. Thailand

7. Malaysia

8. Indonesia

9. New Zealand

Latin America

1. Brazil

2. Mexico

3. Argentina

Middle East & Africa

1. South Africa

2. Saudi Arabia

3. United Arab Emirates

Company Insights:

1. Overview

2. Operating business segments

3. Product portfolio & Product Launch in Last 1 Year

4. Recent Developments

5. Revenue

Companies Covered:

1. Ajanta Pharma Limited

2. Akorn Operating Company LLC

3. Alembic Pharmaceutical Ltd.

4. Cipla Inc.

5. Indoco Remedies Ltd.

6. Johnson & Johnson

7. Novartis AG

8. Ocular Therapeutix, Inc.

9. Sun Pharmaceutical Industries Ltd.

10. Teva Pharmaceutical Industries Ltd.

Table of Contents

1. Introduction

2. Research Methodology

3. Executive Summary

4. Market Dynamics

  • 4.1 Growth Drivers
  • 4.2 Challenges

5. Global Allergic Conjunctivitis Market

6. Global Allergic Conjunctivitis Market Share Analysis

  • 6.1 By Disease Types
  • 6.2 By Drugs Class
  • 6.3 By Distribution Channels
  • 6.4 By Country

7. Disease Types

  • 7.1 Seasonal ALLERGIC Conjunctivitis (SAC)
  • 7.2 Perennial Allergic Conjunctivitis (PAC)

8. Drugs Class

  • 8.1 Antihistamines & Mast Cell Stabilizers
  • 8.2 Corticosteroids
  • 8.3 Others

9. Distribution Channels

  • 9.1 Hospital Pharmacies
  • 9.2 Online Pharmacies
  • 9.3 Retail Pharmacies & Drug Stores
  • 9.4 Others

10. Countries

  • 10.1 North America
    • 10.1.1 United States
    • 10.1.2 Canada
  • 10.2 Europe
    • 10.2.1 France
    • 10.2.2 Germany
    • 10.2.3 Italy
    • 10.2.4 Spain
    • 10.2.5 United Kingdom
    • 10.2.6 Belgium
    • 10.2.7 Netherlands
    • 10.2.8 Turkey
  • 10.3 Asia Pacific
    • 10.3.1 China
    • 10.3.2 Japan
    • 10.3.3 India
    • 10.3.4 Australia
    • 10.3.5 South Korea
    • 10.3.6 Thailand
    • 10.3.7 Malaysia
    • 10.3.8 Indonesia
    • 10.3.9 New Zealand
  • 10.4 Latin America
    • 10.4.1 Brazil
    • 10.4.2 Mexico
    • 10.4.3 Argentina
  • 10.5 Middle East & Africa
    • 10.5.1 South Africa
    • 10.5.2 Saudi Arabia
    • 10.5.3 United Arab Emirates

11. Porter's Five Forces Analysis

  • 11.1 Bargaining Power of Buyers
  • 11.2 Bargaining Power of Suppliers
  • 11.3 Degree of Competition
  • 11.4 Threat of New Entrants
  • 11.5 Threat of Substitutes

12. SWOT Analysis

  • 12.1 Strength
  • 12.2 Weakness
  • 12.3 Opportunity
  • 12.4 Threats

13. Key Players Analysis

  • 13.1 Ajanta Pharma Limited
    • 13.1.1 Overview
    • 13.1.2 Operating business segments
    • 13.1.3 Product portfolio & Product Launch in Last 1 Year
    • 13.1.4 Recent Developments
    • 13.1.5 Revenue
  • 13.2 Akorn Operating Company LLC
    • 13.2.1 Overview
    • 13.2.2 Operating business segments
    • 13.2.3 Product portfolio & Product Launch in Last 1 Year
    • 13.2.4 Recent Developments
    • 13.2.5 Revenue
  • 13.3 Alembic Pharmaceutical Ltd.
    • 13.3.1 Overview
    • 13.3.2 Operating business segments
    • 13.3.3 Product portfolio & Product Launch in Last 1 Year
    • 13.3.4 Recent Developments
    • 13.3.5 Revenue
  • 13.4 Cipla Inc.
    • 13.4.1 Overview
    • 13.4.2 Operating business segments
    • 13.4.3 Product portfolio & Product Launch in Last 1 Year
    • 13.4.4 Recent Developments
    • 13.4.5 Revenue
  • 13.5 Indoco Remedies Ltd.
    • 13.5.1 Overview
    • 13.5.2 Operating business segments
    • 13.5.3 Product portfolio & Product Launch in Last 1 Year
    • 13.5.4 Recent Developments
    • 13.5.5 Revenue
  • 13.6 Johnson & Johnson
    • 13.6.1 Overview
    • 13.6.2 Operating business segments
    • 13.6.3 Product portfolio & Product Launch in Last 1 Year
    • 13.6.4 Recent Developments
    • 13.6.5 Revenue
  • 13.7 Novartis AG
    • 13.7.1 Overview
    • 13.7.2 Operating business segments
    • 13.7.3 Product portfolio & Product Launch in Last 1 Year
    • 13.7.4 Recent Developments
    • 13.7.5 Revenue
  • 13.8 Ocular Therapeutix, Inc.
    • 13.8.1 Overview
    • 13.8.2 Operating business segments
    • 13.8.3 Product portfolio & Product Launch in Last 1 Year
    • 13.8.4 Recent Developments
    • 13.8.5 Revenue
  • 13.9 Sun Pharmaceutical Industries Ltd.
    • 13.9.1 Overview
    • 13.9.2 Operating business segments
    • 13.9.3 Product portfolio & Product Launch in Last 1 Year
    • 13.9.4 Recent Developments
    • 13.9.5 Revenue
  • 13.10 Teva Pharmaceutical Industries Ltd.
    • 13.10.1 Overview
    • 13.10.2 Operating business segments
    • 13.10.3 Product portfolio & Product Launch in Last 1 Year
    • 13.10.4 Recent Developments
    • 13.10.5 Revenue